Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
To, B. [1 ]
Farid, S. [1 ]
Zhao, S. [1 ]
Li, M. [1 ]
Amirmokhtari, N. [1 ]
Wei, L. [1 ]
Memmott, R. [1 ]
Alahmadi, A. [1 ]
He, K. [1 ]
Kaufman, J. [1 ]
Roof, L. [1 ]
Shields, P. [1 ]
Carbone, D. [1 ]
Otterson, G. [1 ]
Presley, C. [1 ]
Owen, D. [1 ]
机构：
[1] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
alectinib; dose reduction; CNS disease;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.10
引用
收藏
页码：S644 / S645
页数：2
相关论文
共 50 条
  • [41] IMAGE CHARACTERISTICS OF ALK-POSITIVE NON SMALL CELL LUNG CANCER
    Oyakawa, Takuya
    Takahashi, Yoshiaki
    Wakuda, Kazushige
    Kimura, Madoka
    Hisamatsu, Yasushi
    Tokito, Takaaki
    Imai, Hisao
    Akamatsu, Hiroaki
    Taira, Tetsuhiko
    Syukuya, Takehito
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Yamamoto, Nobuyuki
    Endo, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S498 - S498
  • [42] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [43] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [44] Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China
    Yang, X.
    Dong, X.
    Liu, Y.
    Jin, B.
    Wang, J.
    Wang, Y.
    Zhang, Y.
    Zhuo, M.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S663 - S663
  • [45] Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer
    Jahanzeb, Mohammad
    Lin, Huamao M.
    Pan, Xiaoyun
    Yin, Yu
    Baumann, Pia
    Langer, Corey J.
    CLINICAL LUNG CANCER, 2021, 22 (01) : 49 - 57
  • [46] A RETROSPECTIVE ANALYSIS ALK-POSITIVE NON-SMALL-CELL LUNG CARCINOMA (NSCLC)
    Pinto, I. G.
    Graziano, S.
    Gajra, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E22 - E22
  • [47] Exposure-response (ER) analysis of alectinib (ALC) in crizotinib-resistant ALK-positive non-small cell lung cancer (NSCLC).
    Morcos, Peter N.
    Jaminion, Felix
    Guerini, Elena
    Hsu, Joy
    Mercier, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [49] Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
    Reckamp, Karen L.
    Lin, Huamao M.
    Cranmer, Holly
    Wu, Yanyu
    Zhang, Pingkuan
    Walton, Laura J.
    Kay, Stephen
    Cichewicz, Allie
    Neupane, Binod
    Fahrbach, Kyle
    Popat, Sanjay
    Camidge, D. Ross
    FUTURE ONCOLOGY, 2022, 18 (20) : 2499 - 2510
  • [50] Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer
    Watanabe, S.
    Matsumoto, N.
    Koshio, J.
    Ishida, A.
    Tanaka, T.
    Abe, T.
    Ishikawa, D.
    Shoji, S.
    Nozaki, K.
    Ichikawa, K.
    Kondo, R.
    Otsubo, A.
    Aoki, A.
    Kajiwara, T.
    Koyama, K.
    Miura, S.
    Yoshizawa, H.
    Kikuchi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S336 - S336
12345